Production, Expression, Purification, Preclinical Test of Novel Influenza Vaccine

Yiwen Zhao, Labone Akter, Chansonida Uk, Caroline Ng, Xinyuan Chen

Flagellin (FH) platform has been used as to perform hybrid by replacing the surface exposed D3 domain of flagellin. FH virus like particles were prepared by the insertion of flagellin gene into the c/el loop of HBC. This gene has been expressed in the E. coli expression, purification and self-assembly into VLPs. FH-VLP based M2e peptide vaccine elicited more potent anti-M2e antibody responses and conferred significant protection against multiple influenza A viral strains. FH VLP based OVA peptide vaccine elicited more potent CTL responses and protection against lymphoma and melanoma challenges. The preclinical data shows FH VLPs to be highly immunogenic and versatile platform. Our present work is to increase the total amount of FHM2e and producing endo free vaccine without losing mass amount of protein.